An announcement from EchoIQ Limited ( (AU:EIQ) ) is now available.
Echo IQ has secured a collaboration agreement with the Mayo Clinic Platform to advance a validation study for its heart failure clinical decision support solution, EchoSolv HF. This partnership follows a positive engagement with the FDA, providing a clear path towards regulatory clearance. The validation study, which is the final requirement before FDA submission, will assess EchoSolv HF’s ability to detect various forms of heart failure. The collaboration also includes the potential for licensing EchoSolv HF to 30 Mayo Clinic Care Network sites. With heart failure being a significant health issue in the US, the successful deployment of EchoSolv HF could lead to improved patient outcomes and substantial market opportunities.
More about EchoIQ Limited
Echo IQ is an AI and medical technology company focused on developing clinical decision support solutions, particularly for heart failure. The company aims to enhance diagnostic accuracy and patient outcomes through innovative technologies.
YTD Price Performance: 23.91%
Average Trading Volume: 2,151,323
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$161.8M
For an in-depth examination of EIQ stock, go to TipRanks’ Stock Analysis page.